Patents by Inventor Cedric Schneider

Cedric Schneider has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PROCESS FOR THE PREPARATION OF ORTHO-HALOGENATED PHENYLALANINE COMPOUNDS
    Publication number: 20230250049
    Abstract: Process of ortho-halogenation of phenylalanine compounds by C—H activation.
    Type: Application
    Filed: June 22, 2021
    Publication date: August 10, 2023
    Inventors: Jean-François BRIERE, Guillaume JOURNOT, Sébastien COUFOURIER, Alexia VILLE, Julien ANNIBALETTO, Cédric SCHNEIDER, Christophe HOARAU
  • Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl
    Patent number: 8895744
    Abstract: The present invention relates to compounds of formula (I) wherein R1, R2 and R3 are as defined in the description, to their pharmaceutical compositions and use thereof for the treatment of cancer expressing oncogenic ALK protein, particularly anaplastic large cell lymphoma (ALCL), diffuse large B cell lymphoma (DLBCL), inflammatory myofibroblastic tumors (IMT) and non-small cell lung cancer (NSCLC).
    Type: Grant
    Filed: August 27, 2009
    Date of Patent: November 25, 2014
    Assignees: Universita' Degli Studi di Milano-Bicocca, Universite' de Geneve, Universite' Claude Bernard de Lyon 1
    Inventors: Carlo Gambacorti Passerini, Luca Mologni, Leonardo Scapozza, Shaheen Ahmed, Peter G. Goekjian, David Gueyrard, Florence Popowycz, Benoit Joseph, Cedric Schneider, Pierre Garcia
  • ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL
    Publication number: 20110281862
    Abstract: The present invention relates to compounds of formula (I) wherein R1, R2 and R3 are as defined in the description, to their pharmaceutical compositions and use thereof for the treatment of cancer expressing oncogenic ALK protein, particularly anaplastic large cell lymphoma (ALCL), diffuse large B cell lymphoma (DLBCL), inflammatory myofibroblastic tumours (IMT) and non-small cell lung cancer (NSCLC).
    Type: Application
    Filed: August 27, 2009
    Publication date: November 17, 2011
    Applicants: Universita' Degli Studi di Milano - Bicocca, Universite' Claude Bernard de Lyon 1, Universite' de Geneve
    Inventors: Carlo Gambacorti Passerini, Luca Mologni, Leonardo Scapozza, Shaheen Ahmed, Peter G. Goekjian, David Gueyrard, Florence Popowycz, Benoit Joseph, Cedric Schneider, Pierre Garcia